{"id":"glyconiazide","rwe":[{"pmid":"14385614","year":"1954","title":"[Polyneuritis of predominant sensitiveness caused by glyconiazide].","finding":"","journal":"Revue de la tuberculose","studyType":"Clinical Study"}],"tags":[{"label":"glyconiazide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"galatone","offLabel":[],"synonyms":["glyconiazide","galatone","gatalone","glucazide","gluconiazide","gluronazid","gluronazide","guidazide","mycobactyl"],"timeline":[],"approvals":[],"brandName":"Galatone","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"glyconiazide","explanation":"Think of it like a sponge that soaks up water. In the kidneys, there's a sponge-like mechanism that helps reabsorb glucose from the urine back into the bloodstream. Galatone blocks this sponge, allowing excess glucose to be removed from the body.","oneSentence":"Galatone works by inhibiting the reabsorption of glucose in the kidneys, allowing excess glucose to be excreted in the urine.","technicalDetail":"Galatone is a glyconiazide that acts as an SGLT2 inhibitor, blocking the sodium-glucose cotransporter 2 in the proximal convoluted tubule of the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3270","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=glyconiazide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:57:38.820862","biosimilars":[],"competitors":[],"genericName":"glyconiazide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008187","UNII":"D71I145DMC","CHEBI":"CHEBI:135237","UMLSCUI":"C0874072","PUBCHEM_CID":"9571091"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Nephrology"],"biosimilarFilings":[],"recentPublications":[{"date":"1954","pmid":"14385614","title":"[Polyneuritis of predominant sensitiveness caused by glyconiazide].","journal":"Revue de la tuberculose"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Galatone, also known as glyconiazide, is a small molecule drug in the glyconiazide class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Galatone is unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine the safety and efficacy of this compound. As a result, Galatone is not currently available for clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}